ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach.
Looking for a particular ProPhase Labs employee's phone or email?
The ProPhase Labs annual revenue was $12.8 million in 2026.
Ted Karkus is the CEO and Chairman of ProPhase Labs.
33 people are employed at ProPhase Labs.
ProPhase Labs is based in Garden City, New York.
The NAICS codes for ProPhase Labs are [541, 325, 3254, 32, 54, 32541].
The SIC codes for ProPhase Labs are [283, 28].